Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760429 | 0.93 | LMNA (0.54) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL4100201 | 0.86 | ALDH1A1 (0.48) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL9298019 | 0.77 | BLM (0.46) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL5701297 | 0.77 | GABBR2 (0.48) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL15281117 | 0.76 | GABBR2 (0.46) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL17903235 | 0.76 | GABBR2 (0.46) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL4311069 | 0.75 | CA4 (0.38) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL6014054 | 0.75 | LMNA (0.40) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL638964 | 0.74 | ALDH1A1 (0.41) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL13587887 | 0.74 | PPARD (0.57) | LMNABLMCYP3A4NFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1910356-A2 | HIV INTEGRASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | LMNA 3741/4885BLM 3179/4885CYP3A4 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.